Heart failure occurs when the heart is
unable to pump sufficiently to maintain blood flow to meet the body’s needs.
Changes in the pressure of blood through the pulmonary artery can be an
indicator of heart failure or worsening heart failure. Following changes in
blood pressure, heart failure will cause shortness of breath and weight gain.
Heart failure is diagnosed by history of
symptoms and a physical examination with confirmation echocardiology. Heart
failure afflicts 2% of the adult population in developed nations, which
increases to 6 to 10% for those above the age of 65. The highest risk of death
is generally right after diagnosis, at around 35%.
Remote hemodynamic monitoring devices are
implanted into the patient to monitor the blood pressure in the pulmonary
artery. The device takes measurements from inside the body and transmits the
data to a secure website for clinicians to review. The clinicians are then able
to preemptively able to detect heart failure and treat them before symptoms
arise.
Spanning over 377 pages “US
Market Report for Remote Hemodynamic Monitoring Systems 2018 - MedCore” report
covers Executive Summary, U.S. Cardiac Surgery And Heart Valve Device Market
Overview, Competitive Analysis, Market Trends, Research Methodology, Disease
Overview, Product Portfolio, Remote Hemodynamic Monitoring System Market,
Appendix. This report Covered Companies - Edwards Lifesciences, St. Jude
Medical, Medtronic, Maquet, Abiomed, HeartWare Inc., Sorin Group, Terumo,
Abbott Laboratories, Teleflex Medical, Cardiac Assist, AtriCure, W.L. Gore,
SynCardia, Boston Scientific, Cryolife, Others include: Berlin Heart, Cardica,
Chase Medical, Genesee Biomedical, Karl Storz, LifeNet Health, Microline
Surgical, Novadaq, On-X, Saphena Medical, SentreHeart, Vitalitec, etc.
Please visit this link for more details: http://mrr.cm/Upt
Find all Pharma
and Healthcare Reports at: https://www.marketresearchreports.com/pharma-healthcare
No comments:
Post a Comment
Note: only a member of this blog may post a comment.